Revelation Biosciences Inc (REVB) — Cash Flow-to-Debt Ratio
Revelation Biosciences Inc (REVB) has a Cash Flow-to-Debt Ratio of -1.05x as of June 2026, meaning its operating cash flow of $-2.56 Million could theoretically repay -1% of its total liabilities ($2.43 Million) in one year. See REVB FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Revelation Biosciences Inc Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Revelation Biosciences Inc across 10 annual periods. For the full cash flow conversion analysis, see REVB cash generation efficiency.
Annual Cash Flow-to-Debt Ratio for Revelation Biosciences Inc (2016–2025)
Year-by-year debt coverage analysis for Revelation Biosciences Inc. Check cash flow quality index of Revelation Biosciences Inc to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.04x | $-8.27 Million | $2.72 Million | ▲ +68.3% |
| 2024 | -9.57x | $-18.32 Million | $1.91 Million | ▼ -631.2% |
| 2023 | -1.31x | $-7.29 Million | $5.56 Million | ▲ +48.1% |
| 2022 | -2.52x | $-11.22 Million | $4.45 Million | ▲ +51.3% |
| 2021 | -5.18x | $-11.09 Million | $2.14 Million | ▼ -15176.9% |
| 2020 | -0.03x | $-215.07K | $6.34 Million | ▼ -100.0% |
| 2019 | 1561.67x | $41.09 Million | $26.31K | ▲ +10499175.7% |
| 2018 | 0.01x | $32.58 Million | $2.19 Billion | ▲ +17.2% |
| 2017 | 0.01x | $24.25 Million | $1.91 Billion | ▲ +88.8% |
| 2016 | 0.01x | $11.60 Million | $1.73 Billion | — |